Higher SARS-COV-2 spike antibody levels are associated with reduced risk of subsequent symptomatic and severe COVID-19. Jin, Yue; Yang, Fei; Rank, Christopher; Letovsky, Stanley; Ramge, Peter and Jochum, Simon from Roche Information Solutions, Roche Diagnostics GmbH, Roche Diagnostics Solutions, and Roche Diagnostics International presented a poster during ISPOR 2024. The objective was to assess the…

Creating a holistic direct to consumer (DTC) and healthcare provider (HCP) marketing strategy from scratch is a demanding task, especially if you don’t have the clinical expertise to precisely identify the consumers or providers you should be targeting. We’re here to give you 5 simple steps to creating a holistic DTC and HCP targeting strategy…

Characterize the real-world CAR-T patient population by describing demographic and social drivers of health (SDOH) attributes at the time of therapy initiation.

The U.S. generic drug supply is at a critical crossroad. With over 60% of generics made abroad, we face a fragile supply chain. This whitepaper analyzes how immediate tariffs to boost domestic manufacturing risk raising patient costs and disrupting access, and outlines the strategic, phased approach needed to secure our drug supply for the long term.

This study was run to characterize patient demographics, cancer indications, treatment patterns, and survival outcomes in a large cohort of patients receiving ADC therapy.

This content was originally published by DeepIntent.  Healthcare marketing is undergoing a transformation, with data-driven insights now serving as the foundation for how brands connect with consumers and providers. That’s why DeepIntent is excited to spotlight PurpleLab®, a data partner that’s helping pharmaceutical brands and agencies connect with their audiences in more effective and meaningful…

Biomarker testing can drastically extend survival across multiple cancer types. But gaps in adoption persist. Are payers, pharma and policymakers doing enough to ensure these tests actually having an impact in the real world? PurpleLab recently conducted a study, Maximizing Survival: The Real-World Impact of Biomarker Testing in Metastatic NSCLC, to shed light on how…

Collaboration with health data and analytics company enhances pharmaceutical ad campaign targeting and measurement VDX.tv Partners with PurpleLab Collaboration with health data and analytics company enhances pharmaceutical ad campaign targeting and measurement VDX.tv, a global leader in digital advertising solutions, today announced a strategic partnership with PurpleLab®, a leading healthcare analytics company powering evidence-based decisions…

As the healthcare industry continues to face data challenges, PurpleLab® is making significant investments in its data and infrastructure to reinforce its position as a trusted leader in real-world data (RWD). We’ve recently secured several new data sources that will dramatically improve the comprehensiveness and composition of our data.(RWD) and real-world evidence (RWE) earlier in the product lifecycle to inform decision-making.

PurpleLab®, a leading health data and analytics company, announced a strategic partnership with Innovare, a pioneer in hospital-based digital media solutions. Together, the companies are transforming how pharmaceutical brands engage physicians by combining Innovare’s network of 300+ hospitals with PurpleLab’s claims-derived healthcare provider (HCP) affiliation data, which includes over three million opted-in HCPs as well…

Although randomized controlled trials remain a cornerstone of evidence generation, pharmaceutical and biotech companies are increasingly recognizing the necessity of leveraging real-world data
(RWD) and real-world evidence (RWE) earlier in the product lifecycle to inform decision-making.